EDITAS MEDICINE, INC. Proceeds from Stock Plans
EDITAS MEDICINE, INC. (EDIT) reported Proceeds from Stock Plans of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockPlans · last filed 2026-08-05
- EDITAS MEDICINE, INC. proceeds from stock plans for the quarter ending 2025-12-31 was $196.00K, a 26.87% decline year-over-year.
- EDITAS MEDICINE, INC. proceeds from stock plans for the quarter ending 2025-09-30 was $0.00.
- EDITAS MEDICINE, INC. proceeds from stock plans for the quarter ending 2024-12-31 was $268.00K, a 44.63% decline year-over-year.
- EDITAS MEDICINE, INC. proceeds from stock plans for the quarter ending 2024-09-30 was $0.00.
- EDITAS MEDICINE, INC. proceeds from stock plans for fiscal 2025 was $424.00K, a 28.14% decline from fiscal 2024.
- EDITAS MEDICINE, INC. proceeds from stock plans for fiscal 2024 was $590.00K, a 35.80% decline from fiscal 2023.
- EDITAS MEDICINE, INC. proceeds from stock plans for fiscal 2023 was $919.00K, a 6.13% decline from fiscal 2022.
- EDITAS MEDICINE, INC. proceeds from stock plans for fiscal 2022 was $979.00K, a 15.02% decline from fiscal 2021.
| Period end | Proceeds from Stock Plans 3 month | Proceeds from Stock Plans 6 month | Proceeds from Stock Plans 9 month | Proceeds from Stock Plans 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $196.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $196.00K derived: sum of 2 quarters · filed 2026-03-09 | $424.00K 10-K · filed 2026-03-09 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $228.00K 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $228.00K 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $268.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $268.00K derived: sum of 2 quarters · filed 2026-03-09 | $590.00K 10-K · filed 2026-03-09 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $322.00K 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $322.00K 10-Q · filed 2025-08-12 | |||
| 2023-12-31 | $484.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $484.00K derived: sum of 2 quarters · filed 2025-03-05 | $919.00K 10-K · filed 2025-03-05 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $435.00K 10-Q · filed 2024-11-04 | ||
| 2023-06-30 | $435.00K 10-Q · filed 2024-08-07 | |||
| 2022-12-31 | $612.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $612.00K derived: sum of 2 quarters · filed 2025-03-05 | $979.00K 10-K · filed 2025-03-05 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $367.00K 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | $367.00K 10-Q · filed 2023-08-02 | |||
| 2021-12-31 | $626.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $626.00K derived: sum of 2 quarters · filed 2024-02-28 | $1.15M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $526.00K 10-Q · filed 2022-11-02 | ||
| 2021-06-30 | $526.00K 10-Q · filed 2022-08-03 | |||
| 2020-12-31 | $545.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $545.00K derived: sum of 2 quarters · filed 2023-02-22 | $895.00K 10-K · filed 2023-02-22 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $350.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $350.00K 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $337.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $337.00K derived: sum of 2 quarters · filed 2022-02-24 | $620.00K 10-K · filed 2022-02-24 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $283.00K 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $283.00K 10-Q · filed 2020-08-07 | |||
| 2018-12-31 | $318.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $318.00K derived: sum of 2 quarters · filed 2021-02-26 | $680.00K 10-K · filed 2021-02-26 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $362.00K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $362.00K 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |